Pei-Jung Lin, PhD

Roughly one-fifth of supplemental indications were approved many years after a drug’s initial launch, many of which target populations with high unmet medical needs.

Two-thirds of pharmaceutical companies did not proactively release the launch price of their medications from 2022 to 2024.

This review presents a set of evidence-based outcome measures for oncology alternative payment models, drawing on evidence from existing and proposed quality measures.

This study's findings showed that diabetes care remained suboptimal among many patients with multiple chronic conditions and that patient outcomes varied by multimorbidity profile.

Incorporating functional status in diagnosis-based risk adjustment measures may modestly improve overall expenditure prediction for beneficiaries with substantial disabilities, but not prescription cost prediction.